RAD51D and breast cancer: Torres-Esquius et al. (2024) studied patients with germline RAD51C/D mutations and found that in untreated RAD51D-associated breast cancers within their cohort, 66.7% exhibited functional HRD and 90.0% exhibited genomic HRD, respectively.